The Affordable Care Act (ACA) recently navigated another Supreme Court challenge, marking its eighth appearance. The case, Kennedy v. Braidwood Management, did not solely focus on PrEP, an HIV-preventing medication but encompassed over 200 preventive services impacting millions in the U.S. This decision preserved the ACA’s guarantees, but it poses questions about the future balance of expertise and political influence in healthcare administration.
Primarily, the ruling examined whether members of a task force who determine evidence-based preventive services required Senate confirmation as “principal officers.” Both the Biden and Trump administrations contended these members to be “inferior officers,” under the Health and Human Services (HHS) Secretary’s purview. Despite this legal success, it raises concerns about the degree of political control now vested in the HHS Secretary, currently Robert F. Kennedy, Jr., and its implications for scientific integrity in policy decisions.
Reflecting on the ACA’s structure, Justice Brett Kavanaugh’s opinion underscores the Secretary’s decisive control over task force recommendations, questioning whether genuine scientific judgment or political preferences will drive future healthcare coverage decisions. This fear is compounded by Kennedy’s recent actions, like dismissing advisory council members charged with vaccine recommendations.
As the Supreme Court previously curtailed agency deference by overruling Chevron v. Natural Resources Defense Council, the interpretation of agency authority under the ACA remains critical. While the Braidwood decision continues to protect access to preventive care, concerns linger about how future legal challenges might reshape the landscape amid these evolving judicial and executive dynamics.
This decision offers insights into post-Chevron statutory interpretation, highlighting the court’s evolving stance on agency expertise and authority. Kavanaugh’s rationale relies on Congressional intent and agency consistency over decades without requiring explicit legislative limits on removal power, suggesting a more nuanced judicial scrutiny of executive actions.
Consequently, this development in judicial oversight signals potential shifts in how agencies could be expected to function. As the Braidwood opinion quietly affirms the ACA’s durability, the broader discourse on political versus expert control remains unsettled and poised to influence future healthcare governance.
Read the full analysis on SCOTUSblog.